Suppr超能文献

[与日常实践中其他治疗方法相比,含旱金莲和辣根的草药制剂治疗急性鼻窦炎、急性支气管炎和急性尿路感染的疗效及安全性/一项前瞻性队列研究结果]

[Efficacy and safety profile of a herbal drug containing nasturtium herb and horseradish root in acute sinusitis, acute bronchitis and acute urinary tract infection in comparison with other treatments in the daily practice/results of a prospective cohort study].

作者信息

Goos Karl-Heinz, Albrecht Uwe, Schneider Berthold

机构信息

Repha GmbH, Biologische Arzneimittel, Langenhagen.

出版信息

Arzneimittelforschung. 2006;56(3):249-57. doi: 10.1055/s-0031-1296717.

Abstract

PATIENTS AND METHODS

In a prospective cohort study from 251 centers in Germany patients with age of 4 years or above who were treated due to acute sinusitis, bronchitis or urinary tract infections (UTI) in the period from 1st March 2004 - 30th July 2005, were elected. They were included in the study analysis, if they had no exclusion criteria (severe diseases, need for antibiotic therapy, participation in another trial) and came to the final investigation. The patients were treated either with the nasturtium herb and horseradish root containing herbal drug Angocin Anti-Infekt N (test group, n = 1223) or with standard antibiotic therapy (control group, n = 426). Treatment, dosage and treatment duration were determined by the physician in accordance with the patient. 536 subjects (408 test, 128 control patients) suffered from acute sinusitis, 634 subjects (469 test, 165 control patients) from acute bronchitis and 479 subjects (346 test, 133 control patients) from UTI. At study start and end the severity of the symptoms were judged by the investigator and quantified with 4 scores (0 = no symptom, 3 severe symptom). During the treatment information on use of medication, concomitant procedures and adverse events (AEs) in a patient diary. At the end of the study (disease free or after 7-14 days) the patient returned to the investigator, who recorded the vital parameters, finally judged the treatment efficacy and potential persisting symptoms on the basis of score values. Primary efficacy criterion was the change of the complaints quantified by the change of the relative symptom score averaged over all symptoms and related to the baseline value.

RESULTS

In patients with acute sinusitis the mean relative reduction of the averaged symptom score was 81.3% for the test group and 84.6% for the control group, in patients with acute bronchitis the mean reduction was 78.3% for the test group and 80.3% for the control group, in patients with UTI 81.2% for the test group and 87.9% for the control group. The 95% confidence interval for the difference of the expected reductions between test and control group was -8.5% to 1.8% for acute sinusitis, 7.6% to 3.6% for acute bronchitis and -13.1% to -0.1% for UTI. Non-inferiority of the test treatment, i.e. if the lower limit of the 95% confidence interval is greater than 10%, could be stated for acute sinusitis and bronchitis. In UTI the non-inferiority level was exceeded only by 3%. Complementary procedures were less in the test group than in the control group. For 1.5 % of test patients and 6.8% of control patients AEs were observed

CONCLUSION

Therapy with the herbal drug in the indications acute sinusitis, acute bronchitis und acute urinary tract infection is - with regard to its efficacy comparable to the treatment with standard antibiotics. The application of supportive procedures and the administration of concurrent medication were less expressed in the group treated with the herbal drug. In the above mentioned indications the group treated with the herbal drug displayed a clear advantageous safety profile compared to the group treated with standard antibiotics.

摘要

患者与方法

在一项来自德国251个中心的前瞻性队列研究中,选取了2004年3月1日至2005年7月30日期间因急性鼻窦炎、支气管炎或尿路感染(UTI)接受治疗的4岁及以上患者。如果他们没有排除标准(严重疾病、需要抗生素治疗、参与另一项试验)且完成了最终调查,则纳入研究分析。患者分别接受含有旱金莲草和辣根的草药制剂Angocin Anti-Infekt N(试验组,n = 1223)或标准抗生素治疗(对照组,n = 426)。治疗方法、剂量和疗程由医生根据患者情况确定。536名受试者(408名试验组,128名对照组患者)患有急性鼻窦炎,634名受试者(469名试验组,165名对照组患者)患有急性支气管炎,479名受试者(346名试验组,133名对照组患者)患有尿路感染。在研究开始和结束时,由研究者判断症状的严重程度并用4个评分进行量化(0 = 无症状,3 = 严重症状)。在治疗期间,通过患者日记记录用药情况、伴随治疗措施和不良事件(AE)。在研究结束时(疾病痊愈或7 - 14天后),患者返回研究者处,研究者记录生命体征参数,最终根据评分值判断治疗效果和潜在的持续症状。主要疗效标准是通过所有症状的相对症状评分变化并与基线值相关来量化症状的改变。

结果

在急性鼻窦炎患者中,试验组平均症状评分的相对降低率为81.3%,对照组为84.6%;在急性支气管炎患者中,试验组平均降低率为78.3%,对照组为80.3%;在尿路感染患者中,试验组为81.2%,对照组为87.9%。试验组和对照组预期降低率差异的95%置信区间在急性鼻窦炎中为 - 8.5%至1.8%,在急性支气管炎中为7.6%至3.6%,在尿路感染中为 - 13.1%至 - 0.1%。对于急性鼻窦炎和支气管炎,可以认为试验治疗非劣效,即95%置信区间的下限大于10%。在尿路感染中,非劣效水平仅超出3%。试验组的辅助治疗措施少于对照组。试验组1.5%的患者和对照组6.8%的患者观察到不良事件。

结论

在急性鼻窦炎、急性支气管炎和急性尿路感染适应症中,草药治疗在疗效方面与标准抗生素治疗相当。在接受草药治疗的组中,支持性治疗措施的应用和同时用药的情况较少。在上述适应症中,与接受标准抗生素治疗的组相比,接受草药治疗的组显示出明显有利的安全性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验